Fall in the hemoglobin level
The reduction in the hemoglobin level (-0.93±0.92, -0.88±0.79, -0.89±0.97, -0.95±1.23 g/dL; P=0.94) and its % reduction (-6.3±6.2, -5.8±5.2, -5.9±6.3, -6.2±8.2 %; P=0.93) were similar across the patient groups with apixaban, dabigatran, edoxaban, and rivaroxaban (Figure 4).